Bayer's next-gen drug Nubeqa aces survival test in metastatic prostate cancer, putting it in competition with giants
In the battle for market dominance in prostate cancer, Bayer’s Nubeqa has made a late entry into the field but holds high hopes for eventual success. New late-stage data could underscore a second indication, which would bode well for the drug’s chances.
Adding Bayer’s Nubeqa to androgen deprivation therapy and chemotherapy docetaxel cut the risk of death by 32.5% against ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer, the German drug giant said Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.